Rheumatology (ACR), and European League Against Rheumatism (EULAR).\(^1,2,3\)

The core sets of measures developed include assessments and composite indices incorporating use of patient-reported outcomes (PROs) and clinical measures and clinicians’ assessments to quantify disease activity over time.\(^1\) PROs are important indicators of disease activity and variability, and they are increasingly used to evaluate treatment effectiveness. Little is known about PROs that patients with rheumatic conditions find most important to convey their experience with their condition and its treatment.

**Objectives:** To examine PROs selected by patients with rheumatic conditions in the ArthritisPower registry to identify symptoms they found most important to track digitally.

**Methods:** Adult US patients within the ArthritisPower registry with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), osteoporosis (OP), osteoarthritis (OA), and fibromyalgia syndrome (FMS) were invited via email to participate in this study. Enrolled participants (pts) were prompted to select ≤10 PRO symptom measures they felt important to track for their condition at baseline via the ArthritisPower app. At 3 subsequent time points (Month [m] 1, m2, m3), pts were given the option to continue tracking their previously selected PRO measures or to add, remove and/or select different measures. At m3, pts completed an exit survey to prioritize ≤5 measures from all measures selected during study participation and to specify other symptoms not available that they would have wanted to track. Measures were ranked-ordered based on number of pts rating the item as their 1st, 2nd, 3rd, 4th or 5th choice and weighted by multiplying the rank number by its inverse for a single, weighted summary score for each measure. Values were summed across all pts to produce a summary score for each measure.

**Results:** Among pts who completed initial selection of PRO assessments at baseline (N=253), 184 pts confirmed or changed PRO selections across m1-3. Mean (SD) age of pts was 55.7 (9.2) yrs, 89.3% female, 91.3% White, mean disease duration of 116 (10.6) yrs. The majority (64.8%) self-reported OA, followed by RA (48.6%), FMS (40.3%), PsA (26.1%), OP (20.1%), AS (15.8%) and SLE (5.9%), not mutually exclusive, and were similar to the overall ArthritisPower population. The average number of instruments (SD) selected for baseline completion was 7.0 (2.5), 7.1 (2.4) at m1, 7.2 (2.4) at m2, and 7.0 (2.5) at m3. The top 5 PROs ranked by pts overall as most important (weighted summary score) for tracking were Fatigue (71), Physical Function (58), Pain Intensity (50), Pain interference (49), Duration of Morning Joint Stiffness (41) (Figure 1). Fatigue, Physical Function, and Pain were consistently in the top 5 across disease states while Depression was more frequent among pts with OA, AS and FMS. Pts’ PRO selections showed stability over time except for the RA Flare measure which decreased from 70.5% of RA pts at baseline to 13.6% at m3.

**Conclusion:** The symptoms prioritized by pts included fatigue, physical function, pain, and joint stiffness. Pts’ choices were consistent over time. These findings provide insights into symptoms rheumatology patients find most important and that lasted from as less than one week to years. Regarding safety, 40% reported a clear benefit of IAT, mainly in terms of reduced pain and increased joint mobility, but also perceived reduced inflammation, with effect from immediate to 36 hours or even 3 weeks post-injection, as well as increased pain, impaired mobility, rashes, or swelling. Twenty-seven percent had not been informed about benefits or potential complications of IAT, and 73% had not been asked whether they wanted local anaesthetic. Consent was deemed necessary by 82 (41%). Most (65%) had never received an ultrasound (US)-guided injection, and of those who had experienced blinded and guided injections, 42 (63%) preferred US-guided because of increased perceived accuracy and confidence in the procedure. Only 50% reported a clear benefit of IAT, mainly in terms of reduced pain and increased joint mobility, but also perceived reduced inflammation, with effect from immediate to 36 hours or even 3 weeks post-injection, and that lasted from as little as less than one week to years. Regarding safety, 40 (20%) had experienced some complications from IAT, including but not limited to increased pain, impaired mobility, rashes, or swelling.

**Results:** The survey was answered by 200 individuals diagnosed with rheumatoid arthritis (66%), osteoarthritis (21%), spondyloarthritis (10%), psoriatic arthritis (9%), and others (16%). The mean number of IATs received was 7 (SD 8), mainly in the knee (66%), shoulder (42%), and wrist (28%), and primarily with corticosteroids (83%) or hyaluronic acid (16%). Twenty-seven percent had not been informed about benefits or potential complications of IAT, and 73% had not been asked whether they wanted local anaesthetic. Consent was deemed necessary by 82 (41%). Most (65%) had never received an ultrasound (US)-guided injection, and of those who had experienced blinded and guided injections, 42 (63%) preferred US-guided because of increased perceived accuracy and confidence in the procedure. Only 50% reported a clear benefit of IAT, mainly in terms of reduced pain and increased joint mobility, but also perceived reduced inflammation, with effect from immediate to 36 hours or even 3 weeks post-injection, and that lasted from as little as less than one week to years. Regarding safety, 40 (20%) had experienced some complications from IAT, including but not limited to increased pain, impaired mobility, rashes, or swelling.

**Conclusion:** The survey has identified gaps in the IAT procedures, such as a need for clearer information. Patients perceive IAT as relatively safe, though painful, and with varying effect. Suggestions for improving the procedure, including more expertise, should be relayed to professionals and relevant organisations.

**Acknowledgments:** Eular Taskforce grant CL109

**Disclosure of Interests:** IRENE Pittsildido: None declared, Jenny de la Torre-Aboki: None declared, Jacqueline Uson Jaeger: None declared, Esperanza Naredo: None declared, Julie Birt Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Jeffrey Curtis Consultant of: Abbvie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Regeneron, Roche, UCSF, UCB, Jeffrey Curtis Grant/research support from: Abbvie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Regeneron, Roche, UCB

**DOI:** 10.1136/annrheumdis-2020-eular.1016

**Figure 1. Overall Participant Ranking of PRO Selections (weighted summary score) at Study Conclusion**

**References:**
5. J. de la Torre-Aboki, I. Pittsildido, J. Uson Jaeger, J. Birt, J. Curtis, J. Naredo, L. Terslev, M. Boesen, H. Pandi, I. Möller, M. A. D’agostino, W. U. Kampen, T. O’Neill, M. Doherty, F. B. Beranbaum, V. Vardanyan, E. Nikiphorou, S. C. Rodríguez-García, R. Castellanos-Moreira, L. Carmona, A. Cyprus League Against Rheumatism, Nicosia, Cyprus; Universitat de Barcelona, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; Rigshospitalet, Copenhagen, Denmark; Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; University of Leeds, Leeds, United Kingdom; Institut Poal de Reumatologia, Barcelona, Spain; APHP-Université Paris-Saclay Versailles, Inserm, Boulogne-Billancourt, France; Rad. Allianz; Nucléamedizin Spezialklinik Hanover, Germany; Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; AP-HP Sorbonne Université, Inserm, Paris, France; Mikayelyan University Hospital, Yerevan, Armenia; King’s College, London, United Kingdom; Hospital Universitario de la Princesa, Madrid, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; IMussc, Madrid, Spain

**Background:** Intra-articular therapy (IAT) is routinely used in rheumatic and musculoskeletal diseases (RMDs). In order to improve the effectiveness and safety of IAT, it is essential to understand patients’ perceptions and needs.

**Objectives:** To assess the perspectives of those who have experienced IAT, including perceptions on benefits and safety.

**Methods:** A steering committee (including a patient research partner) prepared a 44-item questionnaire based on the information needs of a Taskforce on IAT in adult patients with RMDs. The questionnaire was translated into 11 languages and disseminated via EULAR PARE associations and social media. Persons who had experienced at least two IAT procedures were eligible for survey.

Descriptive statistics were used to summarise results as well as inductive codification of open-ended questions.

**Results:** The survey was answered by 200 individuals diagnosed with rheumatoid arthritis (66%), osteoarthritis (21%), spondyloarthritis (10%), psoriatic arthritis (9%), and others (16%). The mean number of IATs received was 7 (SD 8), mainly in the knee (66%), shoulder (42%), and wrist (28%), and primarily with corticosteroids (83%) or hyaluronic acid (16%). Twenty-seven percent had not been informed about benefits or potential complications of IAT, and 73% had not been asked whether they wanted local anaesthetic. Consent was deemed necessary by 82 (41%). Most (65%) had never received an ultrasound (US)-guided injection, and of those who had experienced blinded and guided injections, 42 (63%) preferred US-guided because of increased perceived accuracy and confidence in the procedure. Only 50% reported a clear benefit of IAT, mainly in terms of reduced pain and increased joint mobility, but also perceived reduced inflammation, with effect from immediate to 36 hours or even 3 weeks post-injection, and that lasted from as little as less than one week to years. Regarding safety, 40 (20%) had experienced some complications from IAT, including but not limited to increased pain, impaired mobility, rashes, or swelling.

**Conclusion:** The survey has identified gaps in the IAT procedures, such as a need for clearer information. Patients perceive IAT as relatively safe, though painful, and with varying effect. Suggestions for improving the procedure, including more expertise, should be relayed to professionals and relevant organisations.

**Acknowledgments:** Eular Taskforce grant CL109

**Disclosure of Interests:** IRENE Pittsildido: None declared, Jenny de la Torre-Aboki: None declared, Jacqueline Uson Jaeger: None declared, Esperanza Naredo: None declared, Julie Birt Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Jeffrey Curtis Consultant of: Abbvie, AstraZeneca, Eli Lilly, Esaote, Glenmark, Novartis, Pfizer, Roche, UCB

**DOI:** 10.1136/annrheumdis-2020-eular.97 on September 18, 2023 by guest. Protected by copyright.
UCB, Paid instructor for: IAG, Image Analysis Group, AbbVie, Eli Lilly, Astra-Zeneca, esateo, Glenmark, Novartis, Pfizer, UCB (scientific advisor). Speakers bureau: Eli Lilly, Esateso, Novartis, Pfizer, UCB, Hemant Pandit Grant/research support from: Glaxo Smith Kline (GSK) for work on Dicolfenac Gel. Speakers bureau: Bristol Myers Squibb for teaching their employees about hip and knee replacement, Ingrid Möller: None declared, Maria Antonietta D’Agostino Consultant of: AbbVie, BMS, Novartis, and Roche, Speakers bureau: AbbVie, BMS, Novartis, and Roche, William Uwe Kampen: None declared, Terence O’Neill: None declared, Michael Doherty Grant/research support from: AstraZeneca funded the Nottingham Sons of Gout study, Consultant of: Advisory boards on gout for Grunenthal and Mallinckrodt, Francis Benenbaum Grant/research support from: TRB Chemedica (through institution), MSD (through institution), Pfizer (through institution), Consultant of: Novartis, MSD, Pfizer, Lilly, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, Bone Therapeutics, Regulaxis, Peptinov, 4P Pharma, Paid instructor for: Sandoz, Speakers bureau: Novartis, MSD, Pfizer, Lilly, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, Sandoz, Valentina Vendayany: None declared, Elena Nikiphorou: None declared, Sebastian C Rodriguez-Garcia Speakers bureau: Novartis Farmaceutica, S.A., Merck Sharp & Dohme España, S.A., Sanofi Aventis, UCB Pharma, Raul Castellanos-Moreira: None declared, Loreto Carmona Grant/research support from: Novartis Farmaceutica SA, Pfizer, S.L.U., Merck Sharp & Dohme España, S.A., Roche Farma, S.A., Sanofi Aventis, AbbVie España Spain, S.L.U., and Laboratorios Gebro Pharma, SA (All through institution) DOI: 10.1136/annrheumdis-2020-eular.97

**SUNDAY, 07 JUNE 2020**

**SUNDAY, 07 JUNE 2020**

**Screening and diagnosis of rheumatic diseases**

**PARE0029**

**THE JOURNEY FROM PATIENT AND PUBLIC ENGAGEMENT (PPE) TO INVOLVEMENT: FACILITATING PATIENT PARTNER RESEARCH WORKSHOPS WITH A FOCUS ON FIBROFOG IN FIBROMYALGIA**

S. Derham1, M. Brooke2,1Royal United Hospitals Bath NHS Foundation Trust, RHNRD Rheumatology Therapies, Bath, United Kingdom; 2Bath Institute for Rheumatic Diseases (BIRD), Patient and Public Engagement (PPE), Bath, United Kingdom

**Background:** The Bath Institute for Rheumatic Diseases (BIRD), a registered charity in the United Kingdom (UK), supports research, education and patient engagement for the benefit of people with rheumatic diseases. Event feedback from two Fibromyalgia Information Days showed patients valued the sessions and were keen to be involved in research. Fibrofog in fibromyalgia was identified by patients as one topic of interest.

**Objectives:** To facilitate Patient Research Partner Workshops to generate research questions and inform the design of clinical research into fibrofog in fibromyalgia.

**Methods:** Three Patient Research Partner Workshops, focusing on fibrofog in fibromyalgia, were run between January 2018 and April 2019. All were co-facilitated by a clinician, SD, and BIRD Patient and Public Engagement (PPE) lead, MB. Ethical approval was not required1. Patients were invited to participate by email. A Patient Partner Information Sheet accompanied the workshop invitation. Audio recordings of the discussions were made to aid data capture, following informed written consent by all workshop participants. Travel expenses were offered to all participants.

**Results:** 25 (n=25) women with fibromyalgia attended the workshops. Workshop 1 (n=5) explored, ‘What areas do you think we should research around fibrofog in fibromyalgia?’ Patient partners felt research into fibrofog in fibromyalgia was needed to identify and validate symptoms, and to inform discussions with healthcare professionals. They also called for research into coping strategies to help with fibrofog symptoms. This reflected similar patient calls for research into fibrofog in fibromyalgia.

Workshop 2 (n=10) and Workshop 3 (n=9) explored ‘How do you think we should research fibrofog in fibromyalgia?’ Both workshops identified a broad range of research questions and designs, reflecting individual experiences, knowledge and symptom severity. Suggested research questions included: How severe is fibrofog for each person? What triggers fibrofog? How does fibrofog affect daily tasks? How does fibrofog affect work? What do people with fibromyalgia, their partners, family members and healthcare professionals understand about fibrofog?

Suggested data collection methods included interviews, focus groups and questionnaires. Use of online surveys or interviews had mixed responses. This reflected computer literacy skills and access to hardware. Discussions around recruitment of participants to future studies revealed a wealth of local knowledge including access to community venues and healthcare facilities, support groups and local networks.

Participants were very satisfied with the workshops, finding them helpful, informative and thought provoking. All wanted to continue their involvement in research.

**Conclusion:** Patient Research Partner Workshops are integral to the generation and delivery of clinical research into fibrofog in fibromyalgia. Research designs need to offer multiple methods of data collection to be as inclusive as possible. Next steps will be to formally recruit Patient Research Partners to co-develop a research grant application to explore fibrofog in fibromyalgia.

**References:**

[1] INVOLVE. Public involvement in research and research ethics commit-tee review V.2 Southampton: INVOLVE/Health Research Authority; 2016

**Methods:** The main goal with the training was to highlight positive examples and to create new knowledge as a group and find methods for inclusion and the second training course, “Anti-oppressive pedagogy and language impact”, was to create conditions and find new methods for the healthcare professionals to apply during their work and allow patients to express what is most important for them to be heard.

**Results:** The main goal with the training was to highlight positive examples and to create new knowledge as a group and find methods for inclusion and the second training course, “Anti-oppressive pedagogy and language impact”, was to create conditions and find new methods for the healthcare professionals to apply during their work and allow patients to express what is most important for them to be heard.

**Conclusion:** If lead patient-led training becomes an obvious and vital part in building and developing the health care system, it will lead to new opportunities and possibilities to better form the health care based on patients’ needs, both during the planning and implementation. Because converting to a patient focused care isn’t just about changing old attitudes and organizational culture, it’s also about building new adapted structures and methods for governing the health care system.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.5544

**SATURDAY, 06 JUNE 2020**

**Involvement and innovation in healthcare**

**PARE0028**

**LEAD PATIENTS – A RESOURCE FOR IMPROVEMENT OF THE HEALTH CARE SYSTEM**

M. Beermann1, K. Nilke Nordlund1, 1The Swedish National Organization for Young Rheumatics, Stockholm, Sweden

**Background:** The project “Lead Patients – a new resource for health” led by researcher Sara Riggare at Karolinska Institutet and financed by Vinnova, the Swedish innovation authority, launched in 2017 and the Swedish National Organization for Young Rheumatics was one out of 14 partners. One of our tasks was to develop training courses for health care staff, and to try out what happens when lead patients are giving the opportunity to educate. We developed and produced nine different courses, and during the Autumn of 2019, we had the chance to try out two of them within the project.

**Objectives:** The aim was to switch the perspective and see what would happen when patients’ expertise and knowledge is used to educate health care professionals and challenge the norm about health care professionals being superior. The objective with first training course, “Teams that enable self-realization”, was to create conditions and find new methods for the healthcare professionals to better support patients with what actually matters to them. The objective with the second training course, “Anti-oppressive pedagogy and language impact”, was to create new knowledge as a group and find methods for inclusion and anti-discrimination.

**Methods:** “Teams that enable self-realization” was conducted as an interactive lecture with a concluding workshop. The lecture was based on results from the Swedish Young Rheumatics Report, teamwork and the Swedish Patient Act. The workshop consisted of a case, where the participants were supposed to come up with a plan for a first meeting and treatment of a patient. “Anti-oppressive pedagogy and language impact” was conducted in two parts, with one week in between the two occasions. The first one was mainly a lecture with background and theory about anti-oppressive pedagogy, norms and power structures, followed by a workshop where the participants analyzed the organizations’ own value principles. The second occasion was a deepened discussion with the purpose of identifying new methods for work and strategies to move forward.

**Results:** The main goal with the training was to highlight positive examples and create creative conditions to be able to identify these new methods and tools. And during the training, there was a great will from the staff to work in a more patient-centered way and let what is most important for the patient to be what is directing the meeting. Some suggested that the patient should be considered a part of the health care team, but that methods are missing for making it work today. There was also a great will to reflect over what consequences the current health care system might have, and to discuss possible changes. It was exciting to see the traditional hierarchy, where patients are seen as passive receivers of care, being challenged for real and letting patients not only talk about “what it’s like to live with a chronic disease” but actually be seen as capable and qualified educators.

**Conclusion:** If lead patient-led training becomes an obvious and vital part in building and developing the health care system, it will lead to new opportunities and possibilities to better form the health care based on patients’ needs, both during the planning and implementation. Because converting to a patient focused care isn’t just about changing old attitudes and organizational culture, it’s also about building new adapted structures and methods for governing the health care system.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.97